Deals this week: MediciNova, Confo Therapeutics, Intra-Cellular Therapies

29th September 2017 (Last Updated September 29th, 2017 00:00)

US-based biopharmaceutical company MediciNova plans to raise up to $200m by issuing securities on occasion.

US-based biopharmaceutical company MediciNova plans to raise up to $200m by issuing securities on occasion.

The company plans to issue one or more offerings, including common stock, warrants, preferred stock and debt securities. It plans to use the proceeds towards general corporate purposes and other corporate expenses.

Belgian drug discovery company Confo Therapeutics has signed an agreement with Danish pharmaceutical company H. Lundbeck to use the former’s proprietary Confo technology for the discovery of novel, small molecule therapeutic compounds.

Confo Therapeutics will receive €5m ($5.94m) in research funding and is eligible to receive additional milestone payments during the first two years of collaboration.

US-based biopharmaceutical company Intra-Cellular Therapies plans to raise $150m through an underwritten public offering of common stock shares.

"US-based biopharmaceutical company Intra-Cellular Therapies plans to raise $150m through an underwritten public offering of common stock shares."

The company plans to use the funds towards the launch and commercialisation of lumateperone.

Cocrystal Pharma plans to raise $150m through a public offering of shares of its common stock, preferred stock, warrants and units.

The US-based biotechnology company plans to use the funds towards working capital and general corporate purposes.

Danish biopharmaceutical company Ascendis Pharma plans to raise $134.9m through a public offering of 3.8 million American Depositary Shares (ADSs) each priced at $35.5.

The company plans to use the funds towards the clinical development and commercialisation of its TransCon Growth Hormone.